Literature DB >> 12411666

Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats.

Toshiaki Aoki1, Toshihisa Sumii, Tatsuro Mori, Xiaoying Wang, Eng H Lo.   

Abstract

BACKGROUND AND
PURPOSE: Most experimental models of cerebral ischemia use mechanical methods of occlusion and reperfusion. However, differences between mechanical reperfusion versus clot thrombolysis may influence reperfusion injury profiles. In this study we compared blood flow recovery, blood-brain barrier (BBB) permeability, and matrix metalloproteinase-9 (MMP-9) expression in cortex after mechanical versus thrombolytic reperfusion in rat focal ischemia.
METHODS: Male spontaneously hypertensive rats were used. Mechanical ischemia/reperfusion was achieved with the use of an intraluminal filament to occlude the middle cerebral artery for 2 hours. Thrombolytic reperfusion was achieved by administering tissue plasminogen activator at 2 hours after embolic focal ischemia. Regional cortical blood flow was monitored by laser-Doppler flowmetry. BBB permeability in cortex was measured by Evans blue dye leakage. Cortical MMP-9 levels were assessed with zymography and immunohistochemistry.
RESULTS: Blood flow recovery during mechanical reperfusion was complete in both central and peripheral areas of ischemic cortex. However, after thrombolysis, reperfusion was incomplete, with moderate recovery in the periphery only. BBB permeability was mainly increased in the central regions of the ischemic cortex after mechanical reperfusion but was increased in both central and peripheral areas after thrombolysis. Overall, MMP-9 levels were higher after embolic versus mechanical ischemia/reperfusion, even though ischemic injury was similar in both models at 24 hours.
CONCLUSIONS: There are significant differences in the profiles of blood flow recovery, BBB leakage, and MMP-9 upregulation in mechanical versus thrombolytic reperfusion after focal ischemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411666     DOI: 10.1161/01.str.0000033932.34467.97

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  75 in total

Review 1.  The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity.

Authors:  George W J Harston; Brad A Sutherland; James Kennedy; Alastair M Buchan
Journal:  J Cereb Blood Flow Metab       Date:  2010-08-25       Impact factor: 6.200

2.  Novel cyclopeptides for the design of MMP directed delivery devices: a novel smart delivery paradigm.

Authors:  El-Farouck Moustoifa; Mohamed-Anis Alouini; Arnaud Salaün; Thomas Berthelot; Aghleb Bartegi; Sandra Albenque-Rubio; Gérard Déléris
Journal:  Pharm Res       Date:  2010-05-08       Impact factor: 4.200

3.  Acoustically enhanced Evans blue dye perfusion in neurological tissues.

Authors:  George K Lewis; William L Olbricht; George K Lewis
Journal:  J Acoust Soc Am       Date:  2008-02-15       Impact factor: 1.840

Review 4.  Blood-brain barrier breakdown and neovascularization processes after stroke and traumatic brain injury.

Authors:  Roshini Prakash; S Thomas Carmichael
Journal:  Curr Opin Neurol       Date:  2015-12       Impact factor: 5.710

5.  Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy.

Authors:  Xiang Fan; Zhanyang Yu; Jianxiang Liu; Ning Liu; Katherine A Hajjar; Karen L Furie; Eng H Lo; Xiaoying Wang
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

Review 6.  Experimental models, neurovascular mechanisms and translational issues in stroke research.

Authors:  E H Lo
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

7.  Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation.

Authors:  Robert H Scannevin; Richard Alexander; Tara Mezzasalma Haarlander; Sharon L Burke; Monica Singer; Cuifen Huo; Yue-Mei Zhang; Diane Maguire; John Spurlino; Ingrid Deckman; Karen I Carroll; Frank Lewandowski; Eric Devine; Keli Dzordzorme; Brett Tounge; Cindy Milligan; Shariff Bayoumy; Robyn Williams; Celine Schalk-Hihi; Kristi Leonard; Paul Jackson; Matthew Todd; Lawrence C Kuo; Kenneth J Rhodes
Journal:  J Biol Chem       Date:  2017-08-31       Impact factor: 5.157

8.  Reversing the deleterious effects of α2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke.

Authors:  Aiilyan K Houng; Dong Wang; Guy L Reed
Journal:  Exp Neurol       Date:  2014-02-18       Impact factor: 5.330

Review 9.  Targeting reactive nitrogen species: a promising therapeutic strategy for cerebral ischemia-reperfusion injury.

Authors:  Xing-miao Chen; Han-sen Chen; Ming-jing Xu; Jian-gang Shen
Journal:  Acta Pharmacol Sin       Date:  2012-07-30       Impact factor: 6.150

10.  Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemia.

Authors:  Sophie Gautier; Thavarak Ouk; Olivier Petrault; Jacques Caron; Régis Bordet
Journal:  Br J Pharmacol       Date:  2009-02-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.